J. Rambaud, Les maladies inflammatoires chroniques de l " intestin, John Libbey Eurotext, vol.178, 1998.

C. Gower-rousseau, J. Salomez, J. Dupas, R. Marti, M. Nuttens et al., Incidence of inflammatory bowel disease in northern France Gut, 1988.

L. Beaugerie, Maladie de Crohn et Rectocolite Hemorragique. Médi-text éd. Paris, 2005.

E. Louis and P. Marteau, Maladies inflammatoires chroniques de l " intestin. Doin. Rueil- Malmaison, 2009.

S. Shivananda, J. Lennard-jones, R. Logan, N. Fear, A. Price et al., Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)., Gut, vol.39, issue.5, pp.690-697, 1996.
DOI : 10.1136/gut.39.5.690

J. Cosnes, C. Gower-rousseau, P. Seksik, and A. Cortot, Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology, vol.140, issue.6, pp.1785-94, 2011.
DOI : 10.1053/j.gastro.2011.01.055

URL : https://hal.archives-ouvertes.fr/hal-00631553

A. Ananthakrishnan, Environmental Risk Factors for Inflammatory Bowel Diseases: A Review, Digestive Diseases and Sciences, vol.141, issue.Suppl 2, pp.367-74
DOI : 10.1007/s10620-014-3350-9

J. Cosnes, P. Seksik, I. Nion-larmurier, L. Beaugerie, and J. Gendre, Prior appendectomy and the phenotype and course of Crohn " s disease, World J Gastroenterol WJG, 2006.

R. Andersson, G. Olaison, C. Tysk, and A. Ekbom, Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001.
DOI : 10.1056/NEJM200103153441104

A. Perrone, Toxicité des AINS pour les patients MICI : mythes ou réalité?, 2014.

Y. Zhang and Y. Li, Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, vol.20, issue.1, pp.91-100, 2014.
DOI : 10.3748/wjg.v20.i1.91

O. Chazouillères, Les manifestations h??patobiliaires au cours des MICI, 2009.
DOI : 10.1007/978-2-287-99247-6_1

K. Rothfuss, E. Stange, and K. Herrlinger, Extraintestinal manifestations and complications in inflammatory bowel diseases, World J Gastroenterol WJG Aug, vol.1412, issue.30, pp.4819-4850, 2006.

S. Larsen, K. Bendtzen, and O. Nielsen, Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management, Annals of Medicine, vol.9, issue.7, 2010.
DOI : 10.2165/00002018-200023050-00006

J. Eaden, K. Abrams, and J. Mayberry, The risk of colorectal cancer in ulcerative colitis: a meta-analysis, Gut, vol.48, issue.4, pp.526-561, 2001.
DOI : 10.1136/gut.48.4.526

P. Lecis, B. Germanà, N. Papa, G. Bertiato, C. Doglioni et al., ANCA and ASCA antibodies in the differential diagnosis between ulcerative rectocolitis and Crohn " s disease], Recenti Prog Med, vol.93, issue.5, pp.308-321, 2002.

R. Panaccione and S. Ghosh, Optimal use of biologics in the management of Crohn " s disease. Ther Adv Gastroenterol, pp.179-89, 2010.

J. Colombel, P. Rutgeerts, W. Reinisch, G. Mantzaris, A. Kornbluth et al., P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy, Journal of Crohn's and Colitis, vol.3, issue.1, pp.45-51, 2009.
DOI : 10.1016/S1873-9946(09)60114-8

C. Rousseaux, B. Lefebvre, L. Dubuquoy, P. Lefebvre, O. Romano et al., Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator???activated receptor-??, The Journal of Experimental Medicine, vol.7, issue.8, pp.1205-1220, 2005.
DOI : 10.1136/gut.51.5.659

URL : https://hal.archives-ouvertes.fr/hal-00187736

. Les-corticoïdes-groupe-d, Étude Thérapeutique des Affections Inflammatoires du Tube Digestif [Internet], Disponible sur, 2014.

L. Derijks, L. Gilissen, P. Hooymans, and D. Hommes, Review article: thiopurines in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics, vol.12, issue.1, pp.715-744, 2006.
DOI : 10.1016/0168-8278(91)90916-Y

. Disponible-sur, Disponible sur : http://www.sante.gouv.fr/IMG/pdf/tableau_dispositif_perenne_3_octobre.pdf 44, tableau dispositif perenne 3 octobre -tableau_dispositif_perenne_3_octobre.pdf [Internet]. [consulté le 5 oct 2014] Takeda reçoit une AMM européenne pour Entyvio® MyPharma Editions | L " Info Industrie & Politique de Santé [Internet]. [consulté le 5 oct 2014]. Disponible sur

R. Et-maladie-de-crohn, Europe autorise l " anticorps vedolizumab, p.3600655

. Full-text, Ciprofloxacine et métronidazole en association dans la maladie de Crohn évolutive, Pulsus Group Inc

J. Casati, B. Toner, E. De-rooy, D. Drossman, and R. Maunder, Concerns of patients with inflammatory bowel disease: a review of emerging themes, Dig Dis Sci, 2000.

A. Searle and P. Bennett, Psychological factors and inflammatory bowel disease: A review of a decade of literature, Psychology, Health & Medicine, vol.13, issue.2, pp.121-156, 2001.
DOI : 10.1111/j.1600-0447.1983.tb09716.x

A. Lamouroux, A. Magnan, and D. Vervloet, Compliance, therapeutic observance and therapeutic adherence: what do we speak about?]. Rev Mal Respir, Feb, vol.22, issue.1, pp.31-35, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00374378

P. Price, Education, psychology and ???compliance???, Diabetes/Metabolism Research and Reviews, vol.27, issue.S1, pp.101-106, 2008.
DOI : 10.1002/dmrr.851

N. Tahri, Treatment adherence and chronic inflammatory bowel diseases]. Presse Médicale Paris Fr 1983, pp.1236-1279, 2007.

C. Jackson, J. Clatworthy, A. Robinson, and R. Horne, Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review, The American Journal of Gastroenterology, vol.94, issue.3, pp.525-564, 2010.
DOI : 10.1038/ajg.2009.685

G. Moody, V. Jayanthi, C. Probert, M. Kay, H. Mayberry et al., Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire, European Journal of Gastroenterology & Hepatology, vol.8, issue.12, pp.1179-83, 1996.
DOI : 10.1097/00042737-199612000-00009

S. Kane and F. Shaya, Medication Non-adherence is Associated with Increased Medical Health Care Costs, Digestive Diseases and Sciences, vol.31, issue.11, pp.1020-1024, 2008.
DOI : 10.1007/s10620-007-9968-0

S. Kane, D. Huo, J. Aikens, and S. Hanauer, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, The American Journal of Medicine, vol.114, issue.1, pp.39-43, 2003.
DOI : 10.1016/S0002-9343(02)01383-9

A. Moradkhani, L. Kerwin, S. Dudley-brown, and J. Tabibian, Disease-Specific Knowledge, Coping, and Adherence in Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.12, issue.10, pp.2972-2979, 2011.
DOI : 10.1007/s10620-011-1714-y

H. Phatak and J. Thomas, Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann Pharmacother, 2006.
DOI : 10.1345/aph.1h153

J. Goodhand, N. Kamperidis, B. Sirwan, L. Macken, N. Tshuma et al., Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.18, issue.Suppl. A, pp.1097-108, 2013.
DOI : 10.1111/apt.12476

R. Bertomoro, P. Mazzocco, K. Vettorato, M. Rumiati, R. Sturniolo et al., Risk factors for non-adherence to medication in inflammatory bowel disease patients, Aliment Pharmacol Ther, vol.27, issue.2, pp.166-72, 2008.

S. Wong, J. Walker, R. Carr, L. Graff, C. I. Promislow et al., The Information Needs and Preferences of Persons with Longstanding Inflammatory Bowel Disease, Canadian Journal of Gastroenterology, vol.26, issue.8, pp.525-556, 2012.
DOI : 10.1155/2012/735386

K. Lesnovska, S. Börjeson, H. Hjortswang, and G. Frisman, What do patients need to know? Living with inflammatory bowel disease, Journal of Clinical Nursing, vol.12, issue.11-12, pp.11-121718
DOI : 10.1111/jocn.12321

R. Opheim, T. Bernklev, M. Fagermoen, M. Cvancarova, and B. Moum, Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway, Scand J Gastroenterol, 2012.

M. Word-edm-, WHO_EDM_TRM_2000.1_fre.pdf?ua=1 66. (Microsoft Word -Rapport M\351d Compl \340 l " AP-HP 19 062012.doc) - Rapport_Med_Compl_AP-HP-05-20122, Disponible surHP-05-20122.pdf 67. Complementary, Alternative, or Integrative Health: What " s In a Name? [Internet]. NCCAM, 2000.

R. Hilsden, M. Verhoef, H. Rasmussen, A. Porcino, and J. Debruyn, Use of complementary and alternative medicine by patients with inflammatory bowel disease, Inflammatory Bowel Diseases, vol.17, issue.2, pp.655-62, 2011.
DOI : 10.1002/ibd.21360

R. Hilsden, J. Meddings, and M. Verhoef, Complementary and Alternative Medicine Use by Patients with Inflammatory Bowel Disease: An Internet Survey, Canadian Journal of Gastroenterology, vol.13, issue.4, pp.327-359, 1999.
DOI : 10.1155/1999/586765

P. Rawsthorne, F. Shanahan, N. Cronin, P. Anton, R. Löfberg et al., An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease (IBD), Gastroenterology, vol.114, issue.5, pp.1298-303, 1999.
DOI : 10.1016/S0016-5085(98)84340-0

P. Rawsthorne, C. I. Graff, L. Bernstein, K. Carr, R. Walker et al., The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products, Gut, vol.61, issue.4, 2012.
DOI : 10.1136/gutjnl-2011-300219

L. Langmead, M. Chitnis, and D. Rampton, Use of Complementary Therapies by Patients with IBD May Indicate Psychosocial Distress, Inflammatory Bowel Diseases, vol.8, issue.3, 2002.
DOI : 10.1097/00054725-200205000-00003

V. Abitbol, P. Lahmek, A. Buisson, A. Olympie, C. Poupardin et al., Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, vol.26, issue.3, pp.288-94, 2014.
DOI : 10.1097/MEG.0000000000000040

A. Blanchet and A. L. Gotman, enquête et ses méthodes : l " entretien, 2001.

J. Ketele and X. Roegiers, Méthodologie du recueil d " informations: Fondements des méthodes d " observation, de questionnaires, d " interviews et d " études de documents, 2009.

J. Cosnes and P. Seksik, Facteurs environnementaux dans la maladie de Crohn. Acta Endosc, pp.679-88, 2006.
DOI : 10.1007/bf03018510

R. Modigliani, Progrès en hépatogastroentérologie. Paris: Doin éditeur, 1988.

L. Yen, J. Wu, P. Hodgkins, R. Cohen, and M. Nichol, Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis, J Manag Care Pharm JMCP, vol.18, issue.9, pp.701-713, 2012.

G. Cullen, F. Donnellan, S. Long, M. Forry, and F. Murray, Perceptions of medication safety among patients with inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.90, issue.9, 2010.
DOI : 10.1016/j.cgh.2008.08.029

C. Selinger, A. Robinson, and R. Leong, Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease, Expert Opinion on Drug Safety, vol.19, issue.6, 2011.
DOI : 10.1016/j.crohns.2009.10.002